RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer

Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical science (1979) 2020-07, Vol.134 (14), p.1973-1990
Hauptverfasser: Wang, Huaiming, Huang, Rongkang, Guo, Wentai, Qin, Xiusen, Yang, Zifeng, Yuan, Zixu, Wei, Yingqi, Mo, Chunlin, Zeng, Zhantao, Luo, Jian, Cai, Jian, Wang, Hui
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1990
container_issue 14
container_start_page 1973
container_title Clinical science (1979)
container_volume 134
creator Wang, Huaiming
Huang, Rongkang
Guo, Wentai
Qin, Xiusen
Yang, Zifeng
Yuan, Zixu
Wei, Yingqi
Mo, Chunlin
Zeng, Zhantao
Luo, Jian
Cai, Jian
Wang, Hui
description Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.
doi_str_mv 10.1042/CS20191174
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1042_CS20191174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32677671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</originalsourceid><addsrcrecordid>eNpF0E1Lw0AQBuBFFFurF3-A7FmM7mc2OZbQqlAUbD2HyWbbriSbsrsq_fcm1g_mMMPw8B5ehC4puaVEsLtiyQjNKVXiCI2pUCTJFE-P0ZhQwRPJGB2hsxDeCGG8n1M04ixVKlV0jD5fnqZJZV1t3QbvfBeNdbiYLeYUG7cFp03A2jQNbu3GQ7Sdu8HWfUD4vsDVWG9N23kTbIgDx9UeR_AbE4fE2WrJeo911_RGR2iwHpQ_RydraIK5-NkT9DqfrYqHZPF8_1hMF4lmgsdEm1xwqDMBmZRVnYta5rVIaaYyrbMUKml4rgklUoi8krT_GE5ACck0aAA-QdeHXO27ELxZlztvW_D7kpJyaK_8b6_HVwe8e69aU__R37r4F3V_alA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</title><source>MEDLINE</source><source>Portland Press Electronic Journals</source><creator>Wang, Huaiming ; Huang, Rongkang ; Guo, Wentai ; Qin, Xiusen ; Yang, Zifeng ; Yuan, Zixu ; Wei, Yingqi ; Mo, Chunlin ; Zeng, Zhantao ; Luo, Jian ; Cai, Jian ; Wang, Hui</creator><creatorcontrib>Wang, Huaiming ; Huang, Rongkang ; Guo, Wentai ; Qin, Xiusen ; Yang, Zifeng ; Yuan, Zixu ; Wei, Yingqi ; Mo, Chunlin ; Zeng, Zhantao ; Luo, Jian ; Cai, Jian ; Wang, Hui</creatorcontrib><description>Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.</description><identifier>ISSN: 0143-5221</identifier><identifier>EISSN: 1470-8736</identifier><identifier>DOI: 10.1042/CS20191174</identifier><identifier>PMID: 32677671</identifier><language>eng</language><publisher>England</publisher><subject>Animals ; Antineoplastic Agents ; Carcinogenesis ; CELF1 Protein - metabolism ; Cell Movement ; Colorectal Neoplasms - metabolism ; Drug Resistance, Neoplasm ; Epithelial-Mesenchymal Transition ; Female ; HCT116 Cells ; HT29 Cells ; Humans ; Male ; Mice ; Mice, Nude ; Middle Aged ; Oxaliplatin ; Proto-Oncogene Protein c-ets-2 - genetics ; Proto-Oncogene Protein c-ets-2 - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>Clinical science (1979), 2020-07, Vol.134 (14), p.1973-1990</ispartof><rights>2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</citedby><cites>FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</cites><orcidid>0000-0003-0086-5795</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3253,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32677671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Huaiming</creatorcontrib><creatorcontrib>Huang, Rongkang</creatorcontrib><creatorcontrib>Guo, Wentai</creatorcontrib><creatorcontrib>Qin, Xiusen</creatorcontrib><creatorcontrib>Yang, Zifeng</creatorcontrib><creatorcontrib>Yuan, Zixu</creatorcontrib><creatorcontrib>Wei, Yingqi</creatorcontrib><creatorcontrib>Mo, Chunlin</creatorcontrib><creatorcontrib>Zeng, Zhantao</creatorcontrib><creatorcontrib>Luo, Jian</creatorcontrib><creatorcontrib>Cai, Jian</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><title>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</title><title>Clinical science (1979)</title><addtitle>Clin Sci (Lond)</addtitle><description>Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.</description><subject>Animals</subject><subject>Antineoplastic Agents</subject><subject>Carcinogenesis</subject><subject>CELF1 Protein - metabolism</subject><subject>Cell Movement</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Drug Resistance, Neoplasm</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Female</subject><subject>HCT116 Cells</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Middle Aged</subject><subject>Oxaliplatin</subject><subject>Proto-Oncogene Protein c-ets-2 - genetics</subject><subject>Proto-Oncogene Protein c-ets-2 - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0143-5221</issn><issn>1470-8736</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1Lw0AQBuBFFFurF3-A7FmM7mc2OZbQqlAUbD2HyWbbriSbsrsq_fcm1g_mMMPw8B5ehC4puaVEsLtiyQjNKVXiCI2pUCTJFE-P0ZhQwRPJGB2hsxDeCGG8n1M04ixVKlV0jD5fnqZJZV1t3QbvfBeNdbiYLeYUG7cFp03A2jQNbu3GQ7Sdu8HWfUD4vsDVWG9N23kTbIgDx9UeR_AbE4fE2WrJeo911_RGR2iwHpQ_RydraIK5-NkT9DqfrYqHZPF8_1hMF4lmgsdEm1xwqDMBmZRVnYta5rVIaaYyrbMUKml4rgklUoi8krT_GE5ACck0aAA-QdeHXO27ELxZlztvW_D7kpJyaK_8b6_HVwe8e69aU__R37r4F3V_alA</recordid><startdate>20200731</startdate><enddate>20200731</enddate><creator>Wang, Huaiming</creator><creator>Huang, Rongkang</creator><creator>Guo, Wentai</creator><creator>Qin, Xiusen</creator><creator>Yang, Zifeng</creator><creator>Yuan, Zixu</creator><creator>Wei, Yingqi</creator><creator>Mo, Chunlin</creator><creator>Zeng, Zhantao</creator><creator>Luo, Jian</creator><creator>Cai, Jian</creator><creator>Wang, Hui</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-0086-5795</orcidid></search><sort><creationdate>20200731</creationdate><title>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</title><author>Wang, Huaiming ; Huang, Rongkang ; Guo, Wentai ; Qin, Xiusen ; Yang, Zifeng ; Yuan, Zixu ; Wei, Yingqi ; Mo, Chunlin ; Zeng, Zhantao ; Luo, Jian ; Cai, Jian ; Wang, Hui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-ce943ad84a855bd94d59d461878cc86ab5e39c0105449b516abe30a7452cacaa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antineoplastic Agents</topic><topic>Carcinogenesis</topic><topic>CELF1 Protein - metabolism</topic><topic>Cell Movement</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Drug Resistance, Neoplasm</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Female</topic><topic>HCT116 Cells</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Middle Aged</topic><topic>Oxaliplatin</topic><topic>Proto-Oncogene Protein c-ets-2 - genetics</topic><topic>Proto-Oncogene Protein c-ets-2 - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Huaiming</creatorcontrib><creatorcontrib>Huang, Rongkang</creatorcontrib><creatorcontrib>Guo, Wentai</creatorcontrib><creatorcontrib>Qin, Xiusen</creatorcontrib><creatorcontrib>Yang, Zifeng</creatorcontrib><creatorcontrib>Yuan, Zixu</creatorcontrib><creatorcontrib>Wei, Yingqi</creatorcontrib><creatorcontrib>Mo, Chunlin</creatorcontrib><creatorcontrib>Zeng, Zhantao</creatorcontrib><creatorcontrib>Luo, Jian</creatorcontrib><creatorcontrib>Cai, Jian</creatorcontrib><creatorcontrib>Wang, Hui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical science (1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Huaiming</au><au>Huang, Rongkang</au><au>Guo, Wentai</au><au>Qin, Xiusen</au><au>Yang, Zifeng</au><au>Yuan, Zixu</au><au>Wei, Yingqi</au><au>Mo, Chunlin</au><au>Zeng, Zhantao</au><au>Luo, Jian</au><au>Cai, Jian</au><au>Wang, Hui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</atitle><jtitle>Clinical science (1979)</jtitle><addtitle>Clin Sci (Lond)</addtitle><date>2020-07-31</date><risdate>2020</risdate><volume>134</volume><issue>14</issue><spage>1973</spage><epage>1990</epage><pages>1973-1990</pages><issn>0143-5221</issn><eissn>1470-8736</eissn><abstract>Colorectal cancer (CRC) is often diagnosed at later stages after it has metastasized to other organs. The development of chemoresistance also contributes to a poor prognosis. Therefore, an increased understanding of the metastatic properties of CRC and chemoresistance could improve patient survival. CUGBP elav-like family member 1 (CELF1) is an RNA-binding protein, which is overexpressed in many human malignant tumors. However, the influence of CELF1 in CRC is unclear. V-ets erythroblastosis virus E26 oncogene homologue 2 (ETS2) is an evolutionarily conserved proto-oncogene known to be overexpressed in a variety of human cancers including CRC. In thespresent tudy, we investigated the association between CELF1 and ETS2 in CRC tumorigenesis and oxaliplatin (L-OHP) resistance. We found a positive correlation between the elevated expression of CELF1 and ETS2 in human CRC tissues. Overexpression of CELF1 increased CRC cell proliferation, migration, and invasion in vitro and in a xenograft tumor growth model in vivo, and induced resistance to L-OHP. In contrast, CELF1 knockdown improved the response of CRC cells to L-OHP. Overexpression of ETS2 increased the malignant behavior of CRC cells (growth, migration, and invasion) and L-OHP resistance in vitro. Moreover, L-OHP resistance induced by CELF1 overexpression was reversed by ETS2 knockdown. The results of luciferase reporter and ribonucleoprotein immunoprecipitation assays indicated that CELF1 up-regulates ETS2 by binding to its 3'-UTR. Taken together, our findings have identified that CELF1 regulates ETS2 in a mechanism that results in CRC tumorigenesis and L-OHP resistance, and CELF1 may be a promising target for overcoming chemoresistance in CRC.</abstract><cop>England</cop><pmid>32677671</pmid><doi>10.1042/CS20191174</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-0086-5795</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0143-5221
ispartof Clinical science (1979), 2020-07, Vol.134 (14), p.1973-1990
issn 0143-5221
1470-8736
language eng
recordid cdi_crossref_primary_10_1042_CS20191174
source MEDLINE; Portland Press Electronic Journals
subjects Animals
Antineoplastic Agents
Carcinogenesis
CELF1 Protein - metabolism
Cell Movement
Colorectal Neoplasms - metabolism
Drug Resistance, Neoplasm
Epithelial-Mesenchymal Transition
Female
HCT116 Cells
HT29 Cells
Humans
Male
Mice
Mice, Nude
Middle Aged
Oxaliplatin
Proto-Oncogene Protein c-ets-2 - genetics
Proto-Oncogene Protein c-ets-2 - metabolism
Xenograft Model Antitumor Assays
title RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T14%3A18%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RNA-binding%20protein%20CELF1%20enhances%20cell%20migration,%20invasion,%20and%20chemoresistance%20by%20targeting%20ETS2%20in%20colorectal%20cancer&rft.jtitle=Clinical%20science%20(1979)&rft.au=Wang,%20Huaiming&rft.date=2020-07-31&rft.volume=134&rft.issue=14&rft.spage=1973&rft.epage=1990&rft.pages=1973-1990&rft.issn=0143-5221&rft.eissn=1470-8736&rft_id=info:doi/10.1042/CS20191174&rft_dat=%3Cpubmed_cross%3E32677671%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32677671&rfr_iscdi=true